Cover Image
市場調查報告書

脈絡膜新生血管的全球市場:2016∼2020年

Global Choroidal Neovascularization Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 305742
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
脈絡膜新生血管的全球市場:2016∼2020年 Global Choroidal Neovascularization Market 2016-2020
出版日期: 2016年02月24日 內容資訊: 英文 56 Pages
簡介

脈絡膜新生血管,由於在眼睛脈絡薄膜形成新的血管,在視網膜下血管成長,阻礙視網膜恰當的功能而造成失明。全球脈絡膜新生血管市場,預計2016∼2020年以年複合成長率6.64%擴大。

本報告提供全球脈絡膜新生血管市場現狀與今後的成長預測,各地區趨勢,以及市場趨勢與課題,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 簡介
  • 病理學
  • 症狀
  • 管理
  • 流行病學

第6章 已經過核准治療方法的產品系列

第7章 開發平台分析

第8章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各RoA市場區隔

第10章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 推動市場的要素

第12章 促進要素的影響

第13章 市場課題

第14章 促進要素及課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 市場佔有率分析
  • 主要供應商分析
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Bayer HealthCare
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR8546

About Choroidal Neovascularization

Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).

Technavio's analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Bayer HealthCare
  • Novartis
  • Regeneron Pharmaceuticals
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • Alcon
  • Allergan
  • Avalanche
  • Bausch and Lomb
  • Gilead Sciences
  • Iconic Therapeutics
  • Lpath
  • Neurotech Pharmaceuticals
  • Ohr Pharmaceutical
  • Opthea
  • Ophthotech
  • PanOptica
  • Pfizer
  • Promedior
  • QLT
  • Quark
  • Resolvyx Pharmaceuticals
  • RXi Pharmaceuticals
  • Sagent Pharmaceuticals
  • Santen
  • Sanwa Kagaku Kenkyusho

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • High cost of treatment
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Disease overview

  • Introduction
  • Pathophysiology
  • Symptoms
  • Management
  • Epidemiology

PART 06: Product portfolio of approved therapies

PART 07: Pipeline analysis

  • OHR-102
  • RTH258
  • Fovista
  • RG7716
  • PF-04523655
  • NT-503
  • LFG316
  • REGN2176-3
  • Zimura
  • LHA510
  • DE-120

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by ROA

  • IV
  • Intravitreal

PART 10: Geographical segmentation

  • Global choroidal neovascularization market by geographical segmentation 2015-2020
  • Choroidal neovascularization market in Americas
  • Choroidal neovascularization market in EMEA
  • Choroidal neovascularization market in APAC

PART 11: Market drivers

  • Growing older population
  • Increased prevalence of chronic diseases
  • High patient and physician satisfaction
  • Increase in diagnosis rate

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of treatment
  • Limited public awareness
  • Side effects associated with treatment options
  • Availability of alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Strategic alliances and M&A
  • Increased initiatives and programs
  • Use of combination therapies
  • Increase in R&D

PART 16: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Bayer HealthCare
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings 7
  • Exhibit 02: Key buying criteria for choroidal neovascularization drugs
  • Exhibit 03: Types of choroidal neovascularization
  • Exhibit 04: Symptoms of choroidal neovascularization
  • Exhibit 05: Treatment options for choroidal neovascularization
  • Exhibit 06: Pipeline portfolio: Global choroidal neovascularization therapeutics
  • Exhibit 07: Global choroidal neovascularization market 2015-2020 ($ billions)
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global choroidal neovascularization market by ROA 2015
  • Exhibit 10: Market segmentation by geography 2015
  • Exhibit 11: Choroid neovascularization market revenue by geography 2015-2020 ($ billions)
  • Exhibit 12: Choroidal neovascularization market in Americas 2015-2020 ($ billions)
  • Exhibit 13: Choroidal neovascularization market in EMEA 2015-2020 ($ billions)
  • Exhibit 14: Choroidal neovascularization market in APAC 2015-2020 ($ millions)
  • Exhibit 15: Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 16: Impact of drivers
  • Exhibit 17: Impact of drivers and challenges
  • Exhibit 18: Vendor ranking of global choroidal neovascularization market 2015
  • Exhibit 19: Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions)
  • Exhibit 20: Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions)
  • Exhibit 21: Roche: Key takeaways
  • Exhibit 22: Novartis' specialty ophthalmic segmentation by revenue 2014
  • Exhibit 23: Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions)
  • Exhibit 24: Novartis: Key takeaways
  • Exhibit 25: Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions)
  • Exhibit 26: Regeneron Pharmaceuticals: Key takeaways
  • Exhibit 27: Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions)
  • Exhibit 28: Bayer HealthCare: Key takeaways
Back to Top